文献速递脊柱关节炎

银屑病关节炎达标治疗与亚临床动脉粥样硬化预防:应选择哪个靶标?

Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

结果显示持续MDA和持续PASDAS LDA与斑块进展减少、总斑块面积增加减少、平均内膜中层厚度降低及反射波增强指数降低相关,而持续DAPSA LDA未见显著血管获益。

要点

  • 持续MDA者颈动脉内膜中层厚度进展显著少于未达标者(P=0.031)。
  • 持续MDA和持续PASDAS LDA对斑块进展等血管参数有保护作用。
  • 持续DAPSA LDA未显示对亚临床动脉粥样硬化进展的显著保护。

核心结论

  • 持续达到MDA或PASDAS LDA,而非持续DAPSA LDA,与亚临床动脉粥样硬化和动脉硬度进展的保护作用相关。
  • 多维度疾病控制可能更有利于最小化PsA患者的心血管风险。

研究设计与样本

  • 为一项以MDA为目标的2年达标治疗研究的事后分析。
  • 共招募101例无显性心血管疾病的连续PsA患者,每年评估高分辨率颈动脉超声和动脉硬度标志物。

主要发现

  • 44%、48%和45%的患者分别达到持续DAPSA LDA、持续PASDAS LDA和持续MDA。
  • 达到持续MDA者颈动脉内膜中层厚度进展显著少于未达到者(P=0.031)。
  • 多变量分析显示,达到持续MDA和持续PASDAS LDA对斑块进展有保护作用,表现为总斑块面积增加减少、平均内膜中层厚度降低和反射波增强指数降低。
  • 达到与未达到持续DAPSA LDA的患者之间,血管参数进展无显著差异。

关键数值与推荐

  • 低疾病活动度(LDA)定义为MDA、DAPSA≤14或PASDAS≤3.2。
  • 持续疾病控制定义为从第12个月至第24个月每次访视均达到上述靶标。

临床怎么用

  • 在PsA达标治疗中,选择MDA或PASDAS作为靶标可能比DAPSA更有利于减少亚临床动脉粥样硬化进展。
  • 对无显性心血管疾病的PsA患者,可考虑将多维度疾病控制纳入心血管风险管理策略。

局限性

  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: PsA patients who achieved sustained minimal disease activity (sMDA) had less subclinical atherosclerosis progression. The vascular effects of achieving other potential treatment targets, including the PsA Disease Activity Score (PASDAS) and the Disease Activity in PsA (DAPSA) score, remained uncertain. This study aimed to compare the vascular effects of achieving different treatment targets in PsA patients. METHOD: This is a post hoc analysis of a 2 year treat-to-target study aimed at MDA. A total of 101 consecutive PsA patients without overt cardiovascular disease were recruited. High-resolution carotid ultrasound and arterial stiffness markers were assessed annually. Low disease activity (LDA) was defined as MDA, DAPSA ≤14 or PASDAS ≤3.2. Sustained disease control was defined as achieving these targets at each visit from month 12 until month 24. RESULTS: Ninety patients [52 male (57.8%), age 50 years (s.d. 11)] who completed 24 months of follow-up were included in this analysis. A total of 44%, 48% and 45% of patients achieved sustained DAPSA LDA (sDAPDA-LDA), sustained PASDAS LDA (sPASDAS-LDA) and sMDA, respectively. Patients who achieved sMDA had significantly less progression of carotid intima-media thickness than those who did not (P = 0.031). Using multivariate analysis, achieving sMDA and sPASDAS-LDA had a protective effect on plaque progression, less increase in total plaque area, reduced mean intima-media thickness and reduced augmentation index after adjusting for covariates. In contrast, no significant differences in the progression of vascular parameters were demonstrated between patients who did or did not achieve sDAPSA-LDA. CONCLUSION: Achieving sMDA/sDASPAS-LDA, but not sDAPSA-LDA, was associated with a protective effect in subclinical atherosclerosis and arterial stiffness progression. A multidimensional domain of disease control might be better in minimizing cardiovascular risk in PsA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cheng IT, Li EK, Wong PC, et al. Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose? Rheumatology (Oxford). 2020. PMID: 32087023. doi:10.1093/rheumatology/keaa025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。